0000887359 false 0000887359 2021-06-01 2021-06-01 iso4217:USD xbrli:shares iso4217:USD xbrli:shares











Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934




Date of Report (Date of Earliest Event Reported): June 1, 2021


Vericel Corporation

(Exact name of registrant as specified in its charter)


Michigan     001-35280   94-3096597

(State or other

jurisdiction of


(Commission File



(I.R.S. Employer

Identification No.)



  64 Sidney Street    
  Cambridge, MA 02139  
  (Address of principal executive offices) (Zip Code)  


Registrant’s telephone number, including area code: (617) 588-5555


Not Applicable

Former name or former address, if changed since last report


Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):


¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)


¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)


¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))


¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


Securities registered pursuant to Section 12(b) of the Act:


Title of each class   Trading Symbol(s)   Name of each exchange on which registered
Common Stock, no par value   VCEL   NASDAQ


Indicate by a check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§240.12b-2 of this chapter). Emerging Growth Company ¨


If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o







Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.


On June 1, 2021, the Board of Directors (the “Board”) of Vericel Corporation (the “Company”), upon the recommendation of its Governance and Nominating Committee (the “Governance Committee”), elected Lisa Wright as a director of the Company and member of the Governance Committee, effective immediately. Ms. Wright will serve on the Board until her successor is duly elected and qualified or until her earlier resignation or removal. In connection with her election, Ms. Wright received an option to purchase 9,127 shares of the Company’s common stock with an exercise price equal to the closing price of the Company’s common stock as reported by the Nasdaq Global Market on the grant date, and 3,651 restricted stock units (“RSUs”). Of the options granted, 3,250 shall vest in equal monthly installments over three years commencing on the date of grant, and the remainder shall vest in equal monthly installments, until the earlier of the date of the Company’s next annual meeting of shareholders or April 27, 2022, subject to continued service through such vesting dates. Of the RSUs granted, 1,300 shall vest as to one-third annual increments over three years commencing on the date of grant, and the remainder shall vest on the earlier of the first anniversary date of the RSU grant or the date of the Company’s next annual meeting of shareholders, subject to continued service through such vesting dates.


Ms. Wright will also receive annual cash compensation and equity grants pursuant to the Company’s director compensation guidelines. Ms. Wright has entered into the Company’s standard form of indemnification agreement, which is filed as Exhibit 10.1 to the Company’s Form 8-K filed on August 31, 2010.


There are no arrangements or understandings between Ms. Wright and any other person pursuant to which Ms. Wright was appointed as a member of the Board. There are no family relationships between Ms. Wright, on the one hand, and any director, executive officer or any other person nominated or chosen by the Company to become a director or executive officer, on the other. There are no related person transactions (within the meaning of Item 404(a) of Regulation S-K promulgated by the Securities and Exchange Commission) between Ms. Wright, on the one hand, and the Company, on the other.


A press release announcing Ms. Wright’s appointment is filed as Exhibit 99.1 hereto.


Following Ms. Wright’s appointment, the Chairman of the Board, Dr. Robert Zerbe, will no longer serve as a member of the Board’s Governance and Nominating Committee.


Item 9.01. Financial Statements and Exhibits.


Exhibit No.   Description
99.1   Press Release of Vericel Corporation, dated June 2, 2021
104   Cover Page Interactive Data File (embedded within the Inline XBRL)







Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


  Vericel Corporation
Date: June 2, 2021 By: /s/ Sean C. Flynn
    Name: Sean C. Flynn

Title: Vice President, General Counsel and Secretary






Exhibit 99.1


Vericel Corporation
64 Sidney Street
Cambridge, MA 02139
T 617 588-5555 F 617 588-5554


Vericel Announces Appointment of Lisa Wright to Board of Directors


CAMBRIDGE, Mass., June 2, 2021 (GLOBE NEWSWIRE) -- Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies for the sports medicine and severe burn care markets, today announced the appointment of Lisa Wright to its Board of Directors, effective immediately. Ms. Wright will serve as a member of the Governance and Nominating Committee of the Board. With the appointment of Ms. Wright, Vericel’s Board is now comprised of eight directors, seven of whom are independent.


Ms. Wright is President and Chief Executive Officer of Community Health Choice, Inc., a managed care organization with approximately 430,000 members and a provider community consisting of over 10,000 physicians and 100 hospitals in the greater Houston, Texas area. Previously, Ms. Wright served as a Regional President, Medicare, at WellCare Health Plans, Inc., President of Dual Special Needs Plan, Medicare-Medicaid Plan and Nursing Facilities at UnitedHealth Group, Inc., and in marketing programs management at Anthem, Inc. Ms. Wright currently serves on the boards of directors of several non-profit organizations. She received a Bachelor of Arts degree in Communication from the University of Kentucky and a Master of Business Administration from the University of Maryland, University College system.


“We are delighted to welcome Lisa to the Vericel Board of Directors,” said Nick Colangelo, President and Chief Executive Officer of Vericel. “Lisa is a highly-experienced executive with a track record of strong strategic, operational and financial performance across a number of leading healthcare organizations. Her extensive experience and deep expertise in the payer and provider aspects of the healthcare system will be tremendously valuable as we continue on our strong growth trajectory in the years ahead.”


“Lisa’s appointment reflects Vericel’s commitment to ensuring that we have a broad set of skills and perspectives on the Board,” said Robert L. Zerbe, M.D., Chairman of the Vericel Board of Directors. “We look forward to benefitting from her healthcare industry experience and expertise as we continue to advance our Company’s strategic and operational objectives and increase shareholder value.”




About Vericel Corporation


Vericel is a leader in advanced therapies for the sports medicine and severe burn care markets. The company markets two cell therapy products in the United States. MACI® (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults. Epicel® (cultured epidermal autografts) is a permanent skin replacement for the treatment of patients with deep dermal or full thickness burns greater than or equal to 30% of total body surface area. The company also holds an exclusive license for North American rights to NexoBrid®, a registration-stage biological orphan product for debridement of severe thermal burns. For more information, please visit the company’s website at www.vcel.com.


Epicel® and MACI® are registered trademarks of Vericel Corporation. NexoBrid® is a registered trademark of MediWound Ltd. and is used under license to Vericel Corporation. © 2021 Vericel Corporation. All rights reserved.


Forward Looking Statements


This press release contains forward-looking statements. Forward-looking statements are subject to risks and uncertainties such as those described in Vericel’s periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


Investor Contacts:

Eric Burns


+1 734-418-4411


Page 2 of 2